搜索结果：Clinical, cosmetic and investigational dermatology

Emerging evidence indicates a robust association between inflammatory dermatoses and mental disorders, likely driven by their combined impact on health and shared pathogenic mechanisms. Establishing the causal relationships between these two types of diseases and investigating their comorbid mechanisms. We performed two-sample Mendelian randomization (TSMR) analyses using genome-wide association study (GWAS) summary statistics, examining causal links between six mental disorders and seven inflammatory dermatoses. To elucidate the underlying molecular basis, we implemented an integrative multi-omics framework comprising summary data-based Mendelian randomization (SMR), three-step SMR, TSMR, Bayesian colocalization, gene enrichment analysis and RNA sequencing data analysis. Meta-analysis and multiple testing correction revealed that genetic predisposition to depression increases the risk of psoriasis, while atopic dermatitis is causally associated with a higher risk of depression. Furthermore, we identified 14 genes potentially mediating the comorbidity between inflammatory dermatoses and mental disorders. Functional enrichment analyses and immune cell colocalization suggested the involvement of immunological pathways. Differential expression of several candidate genes was validated in transcriptomic datasets derived from affected tissues. Mediation analyses identified specific mediators and established their causal relationships with the identified genes. Finally, using genetic evidence and druggability assessments, we prioritized the therapeutic potential of these genes. Causal relationships exist between various inflammatory dermatoses and mental disorders, with the most significant associations observed between depression and psoriasis, as well as between atopic dermatitis and depression. Fourteen genes are implicated in their comorbid mechanisms, with FADS1 and TMEM258 exhibiting the greatest potential as therapeutic targets. Psychodermatological disorders refer to skin diseases that are triggered or exacerbated by the interaction between skin conditions and psychological factors. These disorders include skin symptoms caused by psychological factors and psychological issues triggered by skin diseases. Both aspects intertwine, creating a vicious cycle. To date, no research has comprehensively explained the causal relationships and potential mechanisms behind the comorbidity of inflammatory skin diseases and mental disorders. Our study aims to further investigate these disorders. We examined six common mental disorders—anxiety, depression, bipolar disorder, schizophrenia, post-traumatic stress disorder, and obsessive-compulsive disorder—and seven high-prevalence inflammatory skin diseases, including acne, rosacea, hidradenitis suppurativa, atopic dermatitis, contact dermatitis, eczema, and psoriasis. Through a comprehensive analysis of 26 Genome-Wide Association Study datasets from European populations, we confirmed that depression increases the risk of psoriasis, and that there is a causal relationship between atopic dermatitis and the high risk of depression. We then used Summary-based Mendelian Randomization analysis to identify 14 genes associated with these two comorbidities. The functions of these genes were validated through a series of data at the cellular, DNA, and RNA transcription levels. Finally, we evaluated the druggability of these genes using multiple drug databases. We identified Fatty Acid Desaturase 1 (FADS1) and Transmembrane Protein 258 (TMEM258) as the most promising therapeutic targets. In summary, our findings provide new insights into the comorbid mechanisms between inflammatory skin diseases and mental disorders, paving the way for the development of targeted treatment strategies.

Interferon-β (IFNβ) dysregulation contributes to dermatomyositis (DM) pathogenesis. In a previously published phase 2 study, 12-week treatment with dazukibart, an anti-IFNβ monoclonal antibody, reduced disease activity in moderate-to-severe DM. This prespecified secondary analysis evaluated the rapidity of onset of efficacy of dazukibart in DM at time points before Week 12, which may inform treatment decisions. This is a secondary analysis of a double-blind, randomized, placebo-controlled phase 2 study (NCT03181893). Adults with skin-predominant (SP) or muscle-predominant (MP) DM received placebo or dazukibart (150 mg/600 mg) at baseline and every 4 weeks. Efficacy outcomes assessed at Weeks 1, 4, and 8 included: SP cohort-change from baseline (CFB) in Cutaneous Dermatomyositis Disease Area and Severity Index activity (CDASI-A), 5D-itch, and Dermatology Quality of Life Index (DLQI) and proportion of patients achieving ≥40% decrease in CDASI-A; MP cohort-Mean Total Improvement Score (TIS), CFB in myositis core set measures, and TIS response. In SP cohort (n=57), statistically significant improvement was observed with dazukibart in mean CFB (placebo-adjusted difference) CDASI-A (Week 4; 150 mg: -10.5 [p=0.0006]; 600 mg: -9.7 [p=0.0004]), 5D-itch (Week 1; 600 mg: -2.0 [p=0.0359]), and DLQI (Week 4; 150 mg: -2.8 [p=0.0249]; 600 mg: -2.7 [p=0.0160]). CDASI-A score decreased by ≥40% in 53.3% (dazukibart 150 mg), 42.9% (dazukibart 600 mg), and 7.7% (placebo) patients at Week 4. In MP cohort (n=18), numerical improvements (sample size not powered to detect statistical significance) with dazukibart 600 mg vs placebo in mean TIS (Week 4) and statistically significant improvements in mean CFB creatine kinase levels (Week 4; p=0.0445) and Patient Global Assessment (Week 8; p=0.0470) were observed. At Week 4, 77.8% and 22.2% (dazukibart 600 mg) vs 66.7% and 0 (placebo) patients achieved minimal and major improvement, respectively. Dazukibart induced rapid improvement in key skin- and muscle-related efficacy outcomes of disease activity in patients with DM. The small sample size of the MP cohort warrants a well-powered Phase 3 study to confirm these Phase 2 proof-of-concept results. NCT03181893. Dermatomyositis (DM) is an autoimmune disease that affects skin and muscles. Since currently available treatments have limited efficacy, more effective options are needed. Results from a phase 2 study showed improvement with 12-week treatment with dazukibart, a drug targeting a key immune system regulator called interferon beta (INFβ). In this study, we report the onset of response to dazukibart. In patients with predominantly skin disease (skin cohort), we measured improvement in skin symptoms using Cutaneous Dermatomyositis Disease Area and Severity Index-Activity scores (CDASI-A), itch-relief using 5D-itch scores, and quality of life (QoL) using Dermatology QoL Index scores. We calculated the proportion of patients achieving at least 40% improvement in CDASI-A, indicating an improvement in patient’s QoL. In patients with predominantly muscle disease (muscle cohort), we measured improvement in muscle symptoms using Total Improvement Score (TIS) and assessed the proportion of patients achieving minimal, moderate, or major improvement in TIS. In the skin cohort, dazukibart treatment resulted in significant improvement as early as Week 4 in skin symptoms and QoL and Week 1 in itch relief. At Week 4, improvement in skin symptoms was associated with improvement in QoL (at least 40% improvement in CDASI-A) in more than half of patients treated. In the muscle cohort, dazukibart led to improvement in TIS as early as Week 4 and more than 75% of patients achieved at least minimal improvement with dazukibart. Overall, dazukibart treatment resulted in rapid improvement in important skin and muscle symptoms in patients with DM.

Since its first approval in 1981, tissue-extracted collagen injection technology has become an important method for minimally invasive facial rejuvenation, with substantial clinical experience accumulated particularly in the periorbital area. However, due to significant differences in physicochemical properties and metabolic mechanisms compared to hyaluronic acid, its clinical application still faces limitations in understanding and unique complication risks. Furthermore, no unified technical operating standards currently exist internationally. This standard is based on a synthesis of multicenter expert clinical experience. It systematically outlines the product characteristics, classification, and specifications of tissue-extracted collagen; defines clinical indications, contraindications, and operational precautions; specifies qualification requirements for medical institutions and operating physicians; establishes protocols for pre-operative assessment, regional injection design, post-operative management, and complication prevention and treatment strategies; and proposes multimodal treatment recommendations combining surgery, thread lifting, energy-based devices, and other fillers. Through standardized operating procedures and layered injection techniques, the safety and efficacy of tissue-extracted collagen injection therapy can be effectively improved, reducing the occurrence of complications such as nodules and vascular embolism. Combined treatment strategies further expand the application of collagen in facial rejuvenation, achieving complementary effects and optimizing recovery periods. This operational standard provides systematic and standardized clinical guidance for tissue-extracted collagen facial injection. It contributes to promoting the appropriate application and healthy development of this technology, enhancing overall treatment quality and patient satisfaction.

Comprehensive multicenter data on the distribution and determinants of skin diseases in India remain limited. We aimed to characterize the burden of dermatological conditions and identify demographic, behavioral, and clinical predictors across four geographic regions. A retrospective, observational, multicentric, clinic-based, non-interventional study. About 6169 (including 422 children aged 1-16 years) Patients data were collected from 415 dermatologists databases attending dermatology clinics across the North, South, East, and West regions of India between June and September 2024. Data was collected using standardized case report forms. Skin diseases were classified into seven major categories: fungal, bacterial, viral, parasitic, autoimmune, inflammatory, and allergic; each defined using uniform diagnostic criteria. Logistic regression models identified independent predictors of each disease category. Fungal infections were the most common diagnosis (26.1%), followed by autoimmune (19.4%), inflammatory skin disease (18.4%) and allergic conditions (10.2%). Male sex was associated with higher odds of parasitic (aOR 1.84, 95% CI 1.39-2.45; p < 0.001), bacterial (aOR 1.43, 95% CI 1.15-1.79; p < 0.01), viral (aOR 1.35, 95% CI 1.10-1.67; p < 0.01), and fungal dermatoses (aOR 1.36, 95% CI 1.19-1.55; p < 0.001), and lower odds of inflammatory disease (aOR 0.69, 95% CI 0.60-0.80; p < 0.001). Low income was associated with increased odds of fungal (aOR 1.55, 95% CI 1.20-2.03; p < 0.001), bacterial (aOR 1.74, 95% CI 1.15-2.69; p < 0.05), and viral diseases (aOR 1.60, 95% CI 1.07-2.44; p < 0.05), and lower odds of autoimmune disease (aOR 0.69, 95% CI 0.52-0.92; p < 0.01). Regional differences were observed relative to the East region: inflammatory disease was less frequent in the North (aOR 0.56, 95% CI 0.42-0.76; p < 0.001), while viral disease was more frequent in North, South, and West regions (aORs approximately 2.0-2.7). Allergic disease was more common in the South (aOR 2.06, 95% CI 1.42-3.10; p < 0.001). Older age was modestly associated with autoimmune, allergic, bacterial, and viral disease, while children had a higher burden of parasitic infections. In this large clinic-based study of dermatology patients across India, fungal infections were the most frequent diagnosis and disease patterns varied by sex, income, age, and region. These findings highlight substantial sociodemographic and geographic differences among patients seeking dermatologic care and support the need for region-specific prevention and management strategies in clinical practice.

Thread lifting has emerged as a minimally invasive alternative to surgical facial rejuvenation, providing mechanical tissue repositioning with shorter recovery times. Advances in biomaterials and thread design have improved safety and lifting capacity; however, variability in clinical outcomes persists due to differences in vector design, thread type, tissue manipulation, and anesthesia techniques. These factors may influence complication rates, procedural tolerance, and postoperative downtime, contributing to ongoing concerns regarding the predictability and reproducibility of thread-lifting procedures. To describe the development of a vector-optimized thread-lifting technique (VectorLift) and to compare its clinical performance in an exploratory, real-world, non-randomized comparative study with two commonly used thread-lifting approaches employing different biomaterials and insertion methods. The VectorLift protocol was developed using anatomically guided vector placement, ligament-oriented reinforcement, and optimized local anesthetic infiltration. Over a three-year period, 44 female patients (mean age 47 years) underwent facial thread-lifting procedures. Eighteen patients were treated using the proposed technique with cannulated polydioxanone (PDO) threads, while the remaining patients were treated with either double-needle poly-L-lactic acid (PLA) plus poly(L-lactide-co-glycolide) (PLGA) cone threads or cannulated PLA/polycaprolactone (PCL) threads. Clinical outcomes included recovery time (days of downtime), intraoperative pain levels, patient satisfaction measured using the FACE-Q scale before treatment and two weeks post-procedure, and complication rates including dimpling, bruising, edema, and transient asymmetry. Standardized clinical photographs were obtained before and immediately after treatment. VectorLift was associated with lower reported intraoperative pain, shorter recovery time and lower rates of early postoperative complications compared with the other techniques, while patient satisfaction scores were comparable among groups. Immediate photographic assessment confirmed visible aesthetic improvement without overcorrection. VectorLift is an anatomically guided thread-lifting technique that, in this real-world non-randomized comparative study, was associated with improved procedural tolerance and shorter postoperative downtime while maintaining high patient satisfaction and effective aesthetic outcomes. Further controlled studies with larger patient populations and longer follow-up periods are warranted to confirm these findings.

The etiologies of psoriasis, localized scleroderma (LoS), and systemic lupus erythematosus (SLE) remain incompletely understood. Although skin microbiota are implicated in cutaneous immune homeostasis, their causal relationships with autoimmune skin diseases are unclear. To investigate bidirectional causal associations between skin microbiota and psoriasis, LoS, and SLE. Summary-level genome-wide association study (GWAS) data for 1656 skin microbiome traits were obtained from public resources, and GWAS data for psoriasis, LoS, and SLE were obtained from FinnGen version 9. Two-sample Mendelian randomization (MR) was performed using inverse-variance weighting as the primary method, supplemented by MR-Egger regression, weighted median, simple mode, weighted mode, heterogeneity tests, pleiotropy assessment, MR-PRESSO, and leave-one-out analysis. Forward MR identified skin microbiota traits associated with the risk of psoriasis, LoS, and SLE. Specifically, 4, 5, and 5 microbiota traits were positively associated with these diseases, respectively, whereas 4, 3, and 8 traits were inversely associated. Reverse MR suggested that psoriasis, LoS, and SLE may also influence skin microbiota composition: psoriasis and LoS were associated with increased abundance of 4 and 1 microbiota traits, respectively, and psoriasis, LoS, and SLE were associated with reduced abundance of 8, 6, and 2 traits, respectively. Most significant associations showed no strong evidence of heterogeneity or horizontal pleiotropy. This bidirectional MR study provides genetic evidence supporting reciprocal relationships between skin microbiota and autoimmune skin diseases. The findings are exploratory and require replication in larger multi-ancestry cohorts and functional validation before clinical translation.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder which significantly impairs quality of life due to persistent pruritus, sleep disturbance, and recurrent flares. Conventional systemic therapies, such as cyclosporine and methotrexate, often provide inadequate itch and disease control, with limited safety and poor long-term tolerability. The introduction of targeted small-molecule therapies, particularly Janus kinase (JAK) inhibitors, has substantially transformed AD management by enabling rapid itch relief and sustained clinical improvements. Abrocitinib, an oral selective JAK1 inhibitor, has demonstrated rapid and clinically meaningful reduction in pruritus, improvement in skin lesions, and a favorable benefit-risk profile in pivotal clinical trials. However, guidance regarding its optimal real-world use in Indian patients remains limited. This expert recommendation aims to provide practical, experience-based recommendations for the initiation, dosing, monitoring, and long-term management of abrocitinib in patients with moderate-to-severe AD in India. A multistep approach was employed, including a targeted literature review conducted between September and November 2025, a nationwide survey of 36 experienced dermatologists, and two virtual expert panel meetings involving 10 senior clinicians. Experts have identified abrocitinib as a valuable systemic option, particularly for patients with pruritus&#x2011;dominant disease, head and neck involvement, hand eczema, elderly patients with comorbidities, and those inadequately controlled with biologics or other systemic agents. Baseline assessment of hematologic, hepatic, renal, lipid, infectious, cardiovascular, and thrombotic risks was emphasized, with follow-up monitoring recommended at four weeks and following dose modifications. An induction dose of 200 mg once daily was preferred for most patients, with 100 mg reserved for the selected populations. Strategies for maintenance, dose tapering, and treatment transitions were also discussed. Overall, these expert recommendations provide practical real-world guidance supporting the individualized, safe, and effective use of abrocitinib in the Indian clinical setting, while emphasizing the importance of structured monitoring and long-term treatment planning.

Dermatitis cruris pustulosa et atrophicans (DCPA), a chronic skin inflammatory condition involving the shins, is a marginally recognized disorder in Uganda. To describe the clinical manifestation of DCPA and risk factors among populations in southwestern Uganda. The study was conducted in Mbarara and Kabale Regional Referral Hospital Skin Clinics. Demographic data and digital images of affected shins were taken and stored on remote server. In a descriptive cross-sectional study, data was collected from 405 participants from 02/November/2022 to 04/January/2024 and was analyzed using R, a data visualization and statistical computing programming language. Most patients (74.9%) were aged 0-25 years, with a mean age of 21.6 years (SD = 15.1). Females constituted 71.9% of cases. Patients were almost evenly distributed between Mbarara (46.2%) and Kabale (53.8%) Hospitals. The largest affected groups were students (38%) and pupils/infants (25.4%) followed by Farmers (16%) and semiskilled laborers (8.9%). Petroleum jelly was the most topical application (28.6%) while herbal remedies (11.9%), Systemic antibiotics (8.9%) and topical antifungal treatments (5.2%) were less frequently used. DCPA presents with itching, pus discharge, and atrophic skin changes. In southwestern Uganda, it mainly affects young females. In its multifactorial etiopathogenesis oily cosmetic products is a contributory factor.These findings, supported by Mbarara University Data Science Research Hub (MUDSReH), highlight the need for improved diagnostic tools and targeted interventions for DCPA. Further research is needed to assess the broader impact of DCPA in Uganda.

Botulinum toxins type-A (BTX-A) including onabotulinumtoxinA (Botox Cosmetic&#xae;), abobotulinumtoxin A (Dysport&#xae;), and incobotulinumtoxinA (Xeomin&#xae;) have regulatory approval and are widely used as a highly effective non-surgical treatment for dynamic facial wrinkles. BTX-A injections have become a mainstay in aesthetic medicine due to their minimally invasive nature, predictable results, and relatively low risk of complications. Optimizing post-BXT-A skincare is crucial for maximizing results and overall skin health. This randomized double-blind vehicle-controlled, split-face study investigated a novel neuropeptide serum designed to complement BTX-A injections in a post-procedural setting. This is a 10-week, split-face, double-blind, vehicle-controlled randomized study designed to assess the efficacy and tolerability of a topical neuropeptide serum compared to vehicle control as pre- and post-procedural skincare around onabotulinumtoxinA injections in subjects with mild-to-moderate facial lines, facial wrinkles, and rough skin. At pre-treatment, subjects applied either neuropeptide serum or vehicle to one-half of the face randomized in conjunction with moisturizer, cleanser and sunscreen for 14 days. At baseline, subjects received on-label onabotulinumtoxinA injections for glabella and lateral canthal lines, post-injection subjects continued their randomized skincare regimen. Clinical efficacy live grading was assessed at pre-treatment, baseline, weeks 2, 4 and 8. Tolerance and subject self-assessments were conducted during the study. The novel neuropeptide serum demonstrated statistically significant improvement (p < 0.05) compared to vehicle in 18 facial attributes assessed by the clinical dermatologist, including forehead wrinkles, global fine lines, smoothness and radiance at 8&#xa0;weeks post BTX-A injection. Additionally, no tolerability concerns were observed by either the investigator or subjects. Compared to vehicle, the neuropeptides serum's statistical benefits can be seen as early as 2&#xa0;weeks prior to BTX-A injection. The study demonstrated that the neuropeptide serum is an effective complementary product that can be used with BTX-A treatments to achieve enhanced results.

Periungual warts, caused by Human Papillomavirus (HPV) infection, are a therapeutic challenge due to their proximity to the nail matrix and poor drug penetration. Conventional treatments, such as cryotherapy and laser, carry a high risk of nail damage and recurrence, highlighting the need for safer and more effective alternatives. Two patients with refractory periungual warts were included, who had failed multiple previous traditional treatments. One was a 38-year-old male with a 2-year history of periungual warts on the right great toe, and the other was a 60-year-old female with a 1-year history of periungual warts on the right middle finger. Both patients showed no improvement after repeated cryotherapy, topical antiviral drugs, or oral medication. The diagnosis of refractory periungual warts was confirmed clinically based on the characteristic verrucous lesions adjacent to and partially embedded under the nail plate, coupled with a history of treatment failure. Based on the "Wen Tong Qu Shi Du" (warming dredging to dispel dampness and toxin) theory, a combined therapy was adopted: filiform fire needle (0.30 mm &#xd7; 40 mm, heated to incandescence with an alcohol lamp) puncturing the core of the wart every 2&#xa0;weeks, combined with daily soaking in warming-yang and collateral-dredging TCM decoction (10 g Ramulus Cinnamomi, 6 g Rhizoma Zingiberis, 15 g Poria Cocos, 20 g Coix Seed, 12 g Radix Angelicae Sinensis, 9 g Flos Carthami, 15 g Radix Isatidis, 15 g Folium Isatidis; decocted to 200 mL, soaked at 40-45&#xb0;C for 20&#xa0;minutes each time). The 38-year-old male patient achieved complete wart shedding after 3 treatments (6&#xa0;weeks), and the 60-year-old female patient achieved complete wart shedding after 4 treatments (8&#xa0;weeks). No adverse reactions such as nail matrix damage or local infection occurred in either patient during treatment. During the 6-month follow-up, there was no recurrence, and the nail bed was smooth with normal nail plate growth. The combination of filiform fire needle and warming-yang and collateral-dredging TCM soak shows significant efficacy in treating refractory periungual warts. The filiform fire needle directly destroys wart tissue and activates the local immune microenvironment based on the "resolving fire stagnation" principle, while the TCM soak improves the "dampness-stasis-toxin accumulation" pathological state through "warming yang to resolve dampness + dredging collaterals to dissipate stagnation", achieving both symptom and root cause treatment. This therapy avoids the risk of nail matrix damage from traditional physical treatments and overcomes the limitations of poor drug penetration in antiviral therapy, providing a safe and effective TCM external treatment option for clinical practice.

Postcesarean scars are common and may cause persistent symptoms and dissatisfaction. Topical silicone gel is widely used as first-line therapy, but its effects are mainly limited to surface hydration and barrier support. Fractional CO2 laser, by contrast, induces controlled dermal microinjury and collagen remodeling. Comparative evidence for postcesarean scars remains limited. This study compared the effectiveness of fractional CO2 laser versus topical silicone gel for improving scar quality, symptoms, and patient satisfaction. In this retrospective cohort study, 220 women with postcesarean scars were included (112 treated with fractional CO2 laser and 108 with topical silicone gel). Both groups received standard postoperative scar care according to routine clinical practice. The primary outcome was scar quality at 6 months assessed by the Vancouver Scar Scale (VSS). Secondary outcomes included pain, pruritus, tightness, satisfaction, and safety. Between-group differences were analyzed using unadjusted comparisons and analysis of covariance adjusting for baseline VSS and time from surgery to treatment. Sensitivity analyses included additional covariate adjustment and propensity score-adjusted models. At 6 months, the laser group was associated with better scar quality compared with the silicone group (VSS total 4.185 &#xb1; 1.064 vs 4.619 &#xb1; 1.085; unadjusted difference -0.435, P = 0.003). After adjustment, fractional CO2 laser remained associated with a lower VSS total score (adjusted mean difference -0.643; 95% CI -0.891 to -0.395; P < 0.001). Significant improvements were also observed in vascularity, pigmentation, and height/thickness. Laser treatment further reduced pain, pruritus, and tightness, and produced higher patient satisfaction (all P < 0.001). Adverse events were infrequent and comparable between groups. Fractional CO2 laser was associated with greater improvements in postcesarean scar quality and related symptoms at 6 months compared with topical silicone gel, with a comparable safety profile.

To integrate protein quantitative trait loci (BD pQTL) data from the UK Biobank (UKB) and the Icelandic population to investigate the causal relationship between circulating proteins and basal cell carcinoma (BCC), as well as their mediation mechanisms. Bidirectional Mendelian randomization (MR) was performed to assess the causal association between UKB-derived pQTLs and BCC. Protein-protein interaction networks and functional enrichment analyses were applied to identify core pathways. A mediation MR framework was further constructed to model the regulatory axis of "upstream proteins-mediator proteins-BCC", and sensitivity analyses were conducted to ensure robustness. Circulating proteins have a unidirectional causal effect on BCC, and the associated proteins are significantly enriched in immune and inflammatory pathways. A total of 13 UKB pQTLs were identified to potentially affect the risk of BCC through 6 BD pQTLs, and the robustness of the results was confirmed. Among them, STAT3 and GUCA1A emerged as key mediator hubs, each mediating multiple protein pathways (with the highest mediation proportion reaching 15.2%). This study reveals the causal associations between certain UKB pQTLs, BD pQTLs, and BCC, and identifies six BD pQTLs that mediate the effect of UKB pQTLs on BCC through STAT3 and GUCA1A as core mediator proteins, providing new genetic evidence for the precise stratification and targeted intervention of BCC.

To investigate the link between UVB-induced skin photodamage and cuproptosis, and identify key regulatory genes. Transcriptomic data from UVB-irradiated human skin (GSE41078) were obtained from GEO. Differentially expressed genes (DEGs) were identified, followed by GO and KEGG enrichment, and WGCNA. Key regulators were defined by intersecting DEGs, cuproptosis-related genes (CRGs), and the WGCNA module most correlated with photodamage. Single-cell RNA-seq data (GSE289389) were used to assess ATP7A expression in keratinocytes and to infer cell-cell communication (CellChat), focusing on ECM and adhesion signaling. Hub genes were validated via qRT-PCR and Western blot in UVB-induced acute photodamage cells and mouse models. Examination of the GSE41078 dataset revealed 509 DEGs associated with photodamage. WGCNA identified the blue module as most strongly correlated with photodamage. Cross-referencing 978 core module genes with 55 CRGs and 509 DEGs identified a single hub gene, ATPase copper transporting alpha (ATP7A). Single-cell analysis confirmed significant ATP7A downregulation after UVB exposure (p = 1.83 &#xd7; 10-5) and showed that ATP7A-high keratinocytes exhibited stronger integration with stromal cells via enhanced ECM-adhesion signaling (e.g. collagen, laminin), whereas ATP7A-low cells displayed weakened responsiveness to microenvironmental cues. Experimental confirmation suggested that both mRNA and protein expression of ATP7A were markedly diminished in photodamaged cellular and mouse models (P < 0.05), aligning with the computational predictions. This study suggests a potential association between ATP7A downregulation and UVB-induced photodamage with possible relevance to cuproptosis-related pathways. ATP7A downregulation is associated with reduced ECM-adhesion signaling interactions in keratinocytes, as indicated by CellChat. This analysis provides new clues to the mechanism of photodamage and suggests that ATP7A may be involved in the functional regulation of skin photodamage.

Syringocystadenoma papilliferum is an uncommon benign adnexal tumor originating from apocrine or eccrine sweat glands. It frequently occurs on the head and neck and is often associated with nevus sebaceous, posing diagnostic challenges in clinical practice due to its variable clinical presentations. To investigate the clinical and histopathological characteristics and outcomes of five cases with syringocystadenoma papilliferum and to improve the clinical understanding of this disease in combination with the literature. The clinical and histopathological characteristics and outcomes of five Chinese patients with syringocystadenoma papilliferum were retrospectively analyzed. There were two males and three females with an age at onset ranging from 0 to 69 years. All the skin lesions were located on the head and neck, with 4 cases occurring on the scalp and 1 case occurring on the neck. Clinical manifestations were isolated nodules, plaques, or linear, papillary plaques, with skin-colored to light yellowish, yellowish pink, or red. The skin lesions of all cases showed a slow increase with age. The histopathological findings were as follows: the papillary projections covered by double layers of epithelial cells and stroma rich in plasma cells. The pathologies of the two cases suggested syringocystadenoma papilliferum combined with nevus sebaceous. All cases underwent complete surgical excision treatment. Postoperative follow-up duration ranged from 24 to 48 months, with no recurrence observed in surviving cases. Syringocystadenoma papilliferum is a rare cutaneous appendageal tumor, which is easily confused with nevus sebaceous and verrucous lesions. It often occurs on the head and neck. In this small case series, two of five cases demonstrated coexisting syringocystadenoma papilliferum with nevus sebaceous, underscoring the recognized association between these entities. For nevus sebaceous lesions that have persisted for a long time or have undergone morphological changes, the possibility of secondary tumors such as syringocystadenoma papilliferum should be considered. Complete surgical resection with histopathological confirmation is recommended as the definitive management strategy, with postoperative follow-up to monitor for potential recurrence or development of secondary tumors, particularly in cases associated with nevus sebaceous.

Skin diseases are chronic and recurrent conditions that impose substantial disability and long-term psychosocial burden. However, the global burden of pediatric skin diseases has been insufficiently studied. We extracted age-specific data for individuals younger than 20 years from GBD 2021. A comprehensive analytical framework was applied, including Joinpoint regression analysis, SDI frontier analysis, Bayesian age-period-cohort (BAPC) modeling, and ARIMA time-series forecasting to evaluate temporal trends and predict future disease burden. The age definition (<20 years) follows the standard GBD age grouping for children and adolescents. Globally, the burden of skin and subcutaneous diseases increased from 653,365.48 to 860,806.73 DALYs (EAPC = 0.45, 95% CI: 0.43-0.47). ARIMA forecasting suggested that dermatitis and other skin diseases will decline in China and Europe but rise in the United States. Children aged 5-9 years had the lowest burden, while those under 5 years and aged 15-19 years showed higher DALYs, mainly driven by atopic dermatitis and acne. The burden of pediatric skin diseases has generally increased globally, although trends vary across regions and disease categories. Acne and atopic dermatitis are the dominant contributors to disability. These findings provide actionable evidence for prioritizing pediatric dermatology in global and regional public health strategies.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for diabetes and obesity management. The medication-driven weight loss (mdWL) induced by GLP-1RAs may lead to facial hollowing, laxity, and wrinkle accentuation. Minimally invasive strategies are needed to restore facial harmony in this population. To evaluate the effectiveness of poly-L-lactic acid (PLLA-SCA) and hyaluronic acid fillers for facial rejuvenation in women undergoing GLP-1RA-induced mdWL. This retrospective, multicenter, real-world case series included 15 women (aged 30-50 years) from four Latin American countries who used GLP-1RAs for mdWL and were treated with PLLA-SCA and hyaluronic acid filler injections. Outcomes were assessed through clinical photos at baseline and around 85-100 days (D90) using the Facial Laxity Rating Scale (FLRS), Wrinkle Severity Rating Scale (WSRS), Global Aesthetic Improvement Scale (GAIS; participant and investigator assessments), and a satisfaction questionnaire. Safety events were recorded. Participants achieved 17.9% weight reduction from baseline. At D90, FLRS scores decreased from 4.5 (SD 2.2) to 2.6 (SD 1.8; p<0.001), and WSRS scores from 3.1 (SD 1.5) to 1.9 (SD 1.0; p=0.003). Eight patients (53%) reduced FLRS by &#x2265;2 points, and 11 of 13 patients (85%) with baseline WSRS >1 showed improvement. All participants reported aesthetic improvement (pGAIS), with 40% rating "exceptional improvement". Investigator GAIS confirmed improvement in 100% of cases. At D90, 87% were satisfied or very satisfied. No serious adverse events occurred; transient ecchymoses and edema resolved spontaneously within 72&#xa0;hours. The combined use of PLLA-SCA and hyaluronic acid fillers is an effective strategy to correct facial skin laxity, volume loss, and smooth nasolabial fold and wrinkles following GLP-1RA-induced mdWL with a satisfactory safety profile. These findings suggest that a combined injectable approach may be beneficial to address the aesthetic impact of mdWL in real-world clinical practice among Latin Americans.

Androgenetic alopecia (AGA) is the most common type of hair loss, and platelet-rich plasma (PRP) has emerged as a promising therapy. However, preparation methods may influence clinical outcomes. To compare buffy coat and apheresis PRP in terms of laboratory characteristics and treatment efficacy in AGA, and to identify predictors of response. A retrospective analysis was conducted on 747 PRP preparations (514 buffy coat, 233 apheresis) and 163 AGA patients who were eligible for final analysis after screening (87 buffy coat, 76 apheresis). Laboratory indices and PRP parameters were assessed. Clinical efficacy was evaluated by trichoscopy and patient-reported outcomes. Logistic regression was used to determine independent predictors. Apheresis PRP required greater blood volumes and yielded higher platelet concentration (1242&#xd7;109/L vs 1079&#xd7;109/L, P<0.001), total platelet counts, and purity, while buffy coat achieved higher recovery rates. Both methods significantly improved hair density, shaft diameter, and follicular parameters, with no significant differences between groups. Patient-reported improvement was higher in the buffy coat group (51.7% vs 46.1%). Logistic regression identified preparation method (buffy coat: OR=3.41, 95% CI: 1.21-9.65, P=0.021) and treatment frequency (OR=2.01 per session, 95% CI: 1.32-3.07, P=0.001) as independent predictors of response. Sex and platelet concentration showed no significant associations. Both buffy coat and apheresis PRP are effective for AGA. Buffy coat PRP was associated with greater subjective improvement despite lower platelet counts, suggesting that platelet number alone does not determine efficacy. Repeated treatments significantly enhance outcomes, highlighting the importance of treatment frequency in PRP therapy.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with obesity, substantial psychosocial burden, and symptom-related discomfort. Bariatric surgery achieves sustained weight loss and may improve psychological well-being, yet its effect on HS-related quality of life and symptom burden remains uncertain. To evaluate the association of bariatric surgery with psychological well-being, quality of life, and pain among patients with HS using validated patient-reported outcome measures. We conducted a analytical cross-sectional study between January 2024 and January 2025 at King Saud University Medical City, Riyadh, Saudi Arabia. Consecutive adult patients with HS were enrolled after informed consent. Disease severity was assessed using Hurley staging. Participants completed the Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and a visual analog scale (VAS) for pain. Outcomes were compared between patients with and without prior bariatric surgery using independent t-tests and general linear models adjusted for age, sex, Hurley stage, and diagnostic delay. Among 135 participants, 77 (57.0%) were female and 15 (11.1%) had undergone bariatric surgery. Patients with prior bariatric surgery had lower mean DLQI (8.13 vs 8.62), PHQ-9 (5.73 vs 7.50), GAD-7 (5.87 vs 6.31), and VAS pain (2.80 vs 3.69) scores than those without surgery; however, these differences were not statistically significant after adjustment (all p>0.05). DLQI correlated positively with PHQ-9 (r=0.334) and GAD-7 (r=0.323), while pain correlated moderately with DLQI (r=0.546; p<0.001). In this cross-sectional sample, prior bariatric surgery was not associated with statistically significant differences in quality of life, depressive symptoms, anxiety symptoms, or pain after adjustment. However, patients with prior bariatric surgery showed consistently lower mean scores across these outcomes. Larger prospective longitudinal studies with more detailed surgical subgroup data are needed to determine the magnitude and durability of any potential benefit.

Chronic spontaneous urticaria (CSU) is a chronic skin disease characterized by the appearance of wheals with or without angioedema for more than 6&#xa0;weeks. Its troublesome symptomatology, recurrent nature, and long-term treatment can be physically, psychologically, and economically challenging to patients adversely affecting their psychological wellbeing and health-related quality of life (HRQoL). This study aimed at (i) measuring the level of anxiety and depression in patients with CSU, (ii) evaluating their HRQoL, and (iii) assessing the relationship between psychological wellbeing and HRQoL in those patients. In this cross-sectional study, patients with CSU (n=114) were recruited by convenience sampling from the dermatology clinic at King Saud University Medical City (KSUMC) between October 2022 and April 2024. Four datasets were collected from each patient: (i) Sociodemographic, disease-, and medication-related characteristics, (ii) anxiety level using the General Anxiety Disorder 7-Item (GAD-7) Scale, (iii) depression level via the 9-item Patient Health Questionnaire (PHQ-9), and (iv) HRQoL using the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). The mean age was 42 (SD: 12.5) with 90.4% being females. The majority had mild-to-moderate disease activity. Around 8% reported concomitant inducible urticaria while 53.5% reported angioedema. The prevalence of patients with CSU at risk of either Generalized Anxiety Disorder (GAD) or Major Depressive Disorder (MDD) was around 28% for each. Mean CU-Q2oL score was 35.3 (SD: 23.4). Several factors were shown to be significantly associated with higher anxiety and depression levels as well as lower HRQoL including, disease activity, presence of angioedema, drug allergy, and the use of sedative antihistamines. Multivariable regression analysis identified high anxiety and depression levels as significant independent predictors of lower HRQoL in patients with CSU. Clinically significant anxiety and depression are prevalent among patients with CSU and are linked to lower HRQoL in those patients.